Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

601

Address:

ACADIA Pharmaceuticals Inc. 12830 El Camino Real Suite 400 San Diego CA 92130 United States

Website:

Home

Phone:

858-558-2871

Leave a comment

Your email address will not be published. Required fields are marked *